Effects of Ile164 polymorphism of beta2-adrenergic receptor gene on coronary artery disease.

OBJECTIVES This study investigated the relationship between beta(2)-adrenergic receptor (B2AR) Ile164 polymorphism and coronary artery disease (CAD). BACKGROUND B2ARs are crucial to the regulation of vascular tone, and neoangiogenesis is impaired in the presence of isoleucine at position 164 (Ile164) B2AR gene polymorphism. No data deal with the role of the variants at position 164 of the B2AR gene in the setting of CAD. METHODS The study population consisted of 330 patients undergoing percutaneous coronary intervention (PCI). RESULTS The Ile164 polymorphism frequency was higher in CAD (12.1% vs. 3%, p = 0.008) with respect to the control population. We divided our population into 2 groups: group 1 (290 patients, threonine/threonine genotype at position 164 [164Thr/Thr]) and group 2 (40 patients, threonine/isoleucine genotype at position 164 [164Thr/Ile]). Patients of group 2 presented an earlier onset of CAD (56.7 +/- 7.8 vs. 59.5 +/- 10, p = 0.04) and a higher incidence of multivessel disease (25.4% vs. 41%, p = 0.044). At follow-up, group 2 showed a higher incidence of new acute myocardial infarction (17.5% vs. 4.5%, p = 0.001), new PCI (37.5% vs. 13.1%, p < 0.0001), and cardiac death (10% vs. 3.1%, p = 0.036). Cox regression analysis identified Ile164 as an independent predictor of cardiac death (odds ratio [OR]: 3.731, 95% confidence interval [CI]: 1.004 to 13.867, p = 0.049) and an overall major adverse cardiac event (OR: 4.100, 95% CI: 1.945 to 8.640, p = 0.0001). A replication study was done on a population of 150 patients with peripheral artery disease. The presence of the Ile164 allele was associated with a higher incidence of acute myocardial infarction (54.5% vs. 25.2%, p = 0.035) or combined events (acute myocardial infarction, PCI, or coronary artery bypass graft) (63.6% vs. 30.9%, p = 0.027). CONCLUSIONS Our study suggests that the B2AR Ile164 mutant is associated with a more aggressive CAD and adversely affects prognosis in patients undergoing PCI.

[1]  M. Chiariello,et al.  Prevalence, risk factors and cardiovascular comorbidity of symptomatic peripheral arterial disease in Italy. , 2004, Atherosclerosis.

[2]  M. Chiariello,et al.  Ischemic Neoangiogenesis Enhanced by &bgr;2-Adrenergic Receptor Overexpression: A Novel Role for the Endothelial Adrenergic System , 2005, Circulation research.

[3]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[4]  M. Michel,et al.  Adrenergic and muscarinic receptors in the human heart. , 1999, Pharmacological reviews.

[5]  R. Lefkowitz,et al.  Targeting Gbeta gamma signaling in arterial vascular smooth muscle proliferation: a novel strategy to limit restenosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  B. Trimarco,et al.  The PlA1/A2 polymorphism of glycoprotein IIIa and cerebrovascular events in hypertension: increased risk of ischemic stroke in high-risk patients , 2007 .

[7]  M. Reidy,et al.  Kinetics of cellular proliferation after arterial injury. V. Role of acute distension in the induction of smooth muscle proliferation. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[8]  M. Chiariello,et al.  Ischemic Neoangiogenesis Enhanced by β2-Adrenergic Receptor Overexpression , 2005 .

[9]  S. Green,et al.  Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Lefkowitz,et al.  Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. , 1998, Circulation.

[11]  D. Hanahan.  Studies on transformation of Escherichia coli with plasmids. , 1983, Journal of molecular biology.

[12]  Tomohiro Sakamoto,et al.  Echolucent carotid plaques predict future coronary events in patients with coronary artery disease. , 2004, Journal of the American College of Cardiology.

[13]  E. Ongini,et al.  β1 and β2 Adrenoceptors are Involved in Mediating Vasodilation in the Human Coronary Artery , 1993 .

[14]  I. Hall,et al.  Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. , 1995, American journal of respiratory cell and molecular biology.

[15]  H. Bruck,et al.  Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart , 2001, Basic Research in Cardiology.

[16]  V. Fuster,et al.  Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study. , 2005, European heart journal.

[17]  S. Liggett.  beta(2)-adrenergic receptor pharmacogenetics. , 2000, American journal of respiratory and critical care medicine.

[18]  Harold T. Dodge,et al.  Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .

[19]  P. Libby,et al.  The molecular bases of restenosis. , 1997, Progress in cardiovascular diseases.

[20]  S. Green,et al.  A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. , 1993, The Journal of biological chemistry.

[21]  I. Palacios,et al.  Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry. , 2007, European heart journal.

[22]  B. Trimarco,et al.  The Glu27 allele of the β2 adrenergic receptor increases the risk of cardiac hypertrophy in hypertension , 2004, Journal of hypertension.

[23]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[24]  Elena Tremoli,et al.  Carotid intima-media thickness by B-mode ultrasound as surrogate of coronary atherosclerosis: correlation with quantitative coronary angiography and coronary intravascular ultrasound findings. , 2007, European heart journal.

[25]  T. Ogihara,et al.  Quantitative ultrasonic tissue characterization can identify high-risk atherosclerotic alteration in human carotid arteries. , 2000, Circulation.

[26]  K. Kinzler,et al.  A simplified system for generating recombinant adenoviruses. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  K. Leineweber,et al.  Beta2-adrenoceptor gene polymorphisms. , 2005, Pharmacogenetics and genomics.

[28]  S. Liggett.  β2-Adrenergic Receptor Pharmacogenetics , 2000 .

[29]  P. Insel,et al.  Blunted Cardiac Responses to Receptor Activation in Subjects With Thr164Ile &bgr;2-Adrenoceptors , 2001, Circulation.

[30]  B. Trimarco,et al.  The Pl(A1/A2) polymorphism of glycoprotein IIIa and cerebrovascular events in hypertension: increased risk of ischemic stroke in high-risk patients. , 2007, Journal of hypertension.

[31]  K. Koch,et al.  Mast cell infiltration in acute coronary syndromes: implications for plaque rupture. , 1998, Journal of the American College of Cardiology.

[32]  I. Hahntow,et al.  The beta2-adrenoceptor gene and hypertension: is it the promoter or the coding region or neither? , 2006, Journal of hypertension.

[33]  S. Green,et al.  Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. , 1994, Biochemistry.

[34]  David O. Williams,et al.  ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines)—Executive Summary , 2001 .

[35]  O. Arcucci,et al.  β-Blockade and increased dyslipidemia in patients bearing Glu27 variant of β2 adrenergic receptor gene , 2005, The Pharmacogenomics Journal.

[36]  W. Koch,et al.  &bgr;2-Adrenergic Receptor Gene Delivery to the Endothelium Corrects Impaired Adrenergic Vasorelaxation in Hypertension , 2002, Circulation.

[37]  E J Topol,et al.  Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. , 1990, Circulation.

[38]  K A Eagle,et al.  ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coro , 2001, Journal of the American College of Cardiology.